Emerging treatments
Efzofitimod
Efzofitimod, a novel biological immunomodulator, selectively binds neuropilin 2 which is upregulated on immune cells in response to lung inflammation.[85] The European Medicines Agency (EMA) has granted efzofitimod orphan drug designation for the treatment of sarcoidosis. A phase 3 multi-centre, randomised, double-blind, placebo-controlled study in patients with pulmonary sarcoidosis is ongoing.[86]
Aviptadil
Aviptadil is a synthetic form of vasoactive intestinal peptide. Its mechanism of action in sarcoidosis is related to its anti-inflammatory and immunoregulatory effects, which may decrease the inflammatory processes seen in sarcoidosis. Inhaled aviptadil has been granted orphan drug designation for the treatment of sarcoidosis by the EMA and US Food and Drug Administration (FDA). There is, however, a lack of evidence of ongoing clinical research.
Use of this content is subject to our disclaimer